Figure 2.

1 year and 2 year NEDA-3 in CLARITY Extension.

1 year and 2 year endpoints are from Week 48 and Week 96 of CLARITY Extension, respectively. NEDA-3 was defined as no qualifying relapse, no 6 month Expanded Disability Status Scale progression, and no T1 gadolinium-enhancing or active T2 lesions. CC7.0, patients randomized to cladribine tablets 3.5 mg/kg in both CLARITY and CLARITY Extension; CI, confidence interval; CP3.5, patients randomized to cladribine tablets 3.5 mg/kg in CLARITY and placebo in CLARITY Extension; NEDA-3, no evidence of disease activity.